{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T02:26:43Z","timestamp":1783132003648,"version":"3.54.6"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","award":["218960"],"award-info":[{"award-number":["218960"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-global.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology: Global"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jacig.2026.100695","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T16:26:39Z","timestamp":1774628799000},"page":"100695","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world outcomes and corticosteroid sparing with mepolizumab for EGPA or HES"],"prefix":"10.1016","volume":"5","author":[{"given":"Michael E.","family":"Wechsler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kovalszki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"Silver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lior","family":"Seluk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremiah","family":"Hwee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson","family":"da Costa Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei Sheng","family":"Duh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"McCann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy G.","family":"Edgecomb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacig.2026.100695_bib1","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.mayocp.2023.02.013","article-title":"HES and EGPA: two sides of the same coin","volume":"98","author":"Khoury","year":"2023","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacig.2026.100695_bib2","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/s41584-023-00958-w","article-title":"Evidence-based guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis","volume":"19","author":"Emmi","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jacig.2026.100695_bib3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/all.15544","article-title":"Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes","volume":"78","author":"Valent","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.jacig.2026.100695_bib4","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jaci.2023.03.011","article-title":"Unmet needs and evidence gaps in hypereosinophilic syndrome and eosinophilic granulomatosis with polyangiitis","volume":"151","author":"Wechsler","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2026.100695_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2022.12.353","article-title":"Real-world insights on the burden of hypereosinophilic syndrome (HES)","volume":"151","author":"Kovalszki","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2026.100695_bib6","article-title":"Eosinophilic granulomatosis with polyangiitis: patient profiles from a large US allergy practice","volume":"4","author":"Wechsler","year":"2025","journal-title":"J Allergy Clin Immunol Glob"},{"key":"10.1016\/j.jacig.2026.100695_bib7","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.anai.2023.02.022","article-title":"Hypereosinophilic syndrome in Europe: retrospective study of treatment patterns, clinical manifestations, and healthcare resource utilization","volume":"130","author":"Hwee","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jacig.2026.100695_bib8","article-title":"Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases","volume":"14","author":"Del Pozo","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jacig.2026.100695_bib9","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1164\/rccm.201904-0903SO","article-title":"Systematic literature review of systemic corticosteroid use for asthma management","volume":"201","author":"Bleecker","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jacig.2026.100695_bib10","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/acr.24634","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody\u2013associated vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jacig.2026.100695_bib11","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jacig.2026.100695_bib12","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.anai.2024.11.004","article-title":"Real-world mepolizumab treatment in eosinophilic granulomatosis with polyangiitis reduces disease burden in the United States","volume":"134","author":"Mathur","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jacig.2026.100695_bib16","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jaci.2020.08.037","article-title":"Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a phase III, randomized, placebo-controlled trial","volume":"146","author":"Roufosse","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2026.100695_bib17","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacig.2026.100695_bib18","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1016\/j.jaip.2021.07.050","article-title":"Safety and efficacy of mepolizumab in hypereosinophilic syndrome: an open-label extension study","volume":"9","author":"Gleich","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2026.100695_bib19","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/art.43146","article-title":"Long-term safety and efficacy of mepolizumab in eosinophilic granulomatosis with polyangiitis","volume":"77","author":"Wechsler","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jacig.2026.100695_bib20","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/mr\/roae100","article-title":"Real-world safety and effectiveness of mepolizumab for patients with eosinophilic granulomatosis with polyangiitis in Japan: long-term observation of the MARS study","volume":"35","author":"Ishii","year":"2025","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.jacig.2026.100695_bib21","series-title":"SAS\/STAT\u00ae 15.3 user\u2019s guide","year":"2023"},{"key":"10.1016\/j.jacig.2026.100695_bib22","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5152\/TurkThoracJ.2017.16040","article-title":"Clinical and serological features of eosinophilic and vasculitic phases of eosinophilic granulomatosis with poliangiitis: a case series of 15 patients","volume":"18","author":"Y\u0131lmaz","year":"2017","journal-title":"Turk Thorac J"},{"key":"10.1016\/j.jacig.2026.100695_bib23","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1164\/rccm.202007-2721OC","article-title":"Expert consensus on the tapering of oral corticosteroids for the treatment of asthma. A Delphi study","volume":"203","author":"Suehs","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jacig.2026.100695_bib24","doi-asserted-by":"crossref","first-page":"00509","DOI":"10.1183\/23120541.00509-2023","article-title":"Mepolizumab has clinical benefits including oral corticosteroid sparing irrespective of baseline EGPA characteristics","volume":"10","author":"Jayne","year":"2024","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jacig.2026.100695_bib25","article-title":"Oral corticosteroid-sparing effects of mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): results up to 7.4 years from the long-term access programme","volume":"209","author":"Khoury","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jacig.2026.100695_bib26","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa070812","article-title":"Treatment of patients with the hypereosinophilic syndrome with mepolizumab","volume":"358","author":"Rothenberg","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacig.2026.100695_bib27","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jaci.2012.07.055","article-title":"Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes","volume":"131","author":"Roufosse","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2026.100695_bib28","article-title":"Mepolizumab in hypereosinophilic syndrome: a systematic review and meta-analysis","volume":"76","author":"Alves Junior","year":"2021","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.jacig.2026.100695_bib29","series-title":"GSK achieves approval for Nucala (mepolizumab) for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) for adults in the US","year":"2017"},{"key":"10.1016\/j.jacig.2026.100695_bib30","series-title":"FDA approves Nucala as the first and only biologic treatment for hypereosinophilic syndrome (HES)","year":"2020"},{"key":"10.1016\/j.jacig.2026.100695_bib31","doi-asserted-by":"crossref","first-page":"885","DOI":"10.4168\/aair.2020.12.5.885","article-title":"Low-dose mepolizumab effectiveness in patients suffering from eosinophilic granulomatosis with polyangiitis","volume":"12","author":"Vultaggio","year":"2020","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.jacig.2026.100695_bib32","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/art.41943","article-title":"Mepolizumab for eosinophilic granulomatosis with polyangiitis: a European multicenter observational study","volume":"74","author":"Bettiol","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jacig.2026.100695_bib33","article-title":"Observational experience describing the use of mepolizumab in patients with hypereosinophilic syndrome","volume":"191","author":"Duncan","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jacig.2026.100695_bib34","doi-asserted-by":"crossref","first-page":"e707","DOI":"10.1016\/S2665-9913(23)00243-6","article-title":"Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study","volume":"5","author":"Bettiol","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jacig.2026.100695_bib35","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13223-023-00801-7","article-title":"Long-term mepolizumab treatment reduces relapse rates in super-responders with eosinophilic granulomatosis with polyangiitis","volume":"19","author":"Masumoto","year":"2023","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jacig.2026.100695_bib36","doi-asserted-by":"crossref","first-page":"461","DOI":"10.37349\/eaa.2024.00058","article-title":"Long-term efficacy of mepolizumab on eosinophilic granulomatosis with polyangiitis: a retrospective study","volume":"2","author":"Matsuyama","year":"2024","journal-title":"Explor Asthma Allergy"},{"key":"10.1016\/j.jacig.2026.100695_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1457202","article-title":"Long-term efficacy of mepolizumab in patients with eosinophilic granulomatosis with polyangiitis: a propensity score matching analysis in the multicenter REVEAL cohort study","volume":"15","author":"Shiomi","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jacig.2026.100695_bib38","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/j.jaci.2018.11.041","article-title":"Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis","volume":"143","author":"Steinfeld","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2026.100695_bib39","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1182\/blood-2023-179404","article-title":"The phase 3 Natron study evaluating benralizumab in patients with hypereosinophilic syndrome: study design and patient characteristics","volume":"142","author":"Akuthota","year":"2023","journal-title":"Blood"}],"container-title":["Journal of Allergy and Clinical Immunology: Global"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772829326000573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772829326000573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T02:13:27Z","timestamp":1783131207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772829326000573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2772829326000573"],"URL":"https:\/\/doi.org\/10.1016\/j.jacig.2026.100695","relation":{},"ISSN":["2772-8293"],"issn-type":[{"value":"2772-8293","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world outcomes and corticosteroid sparing with mepolizumab for EGPA or HES","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology: Global","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacig.2026.100695","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}],"article-number":"100695"}}